Analyst Price Target Update on Akorn (NASDAQ:AKRX)

Akorn (NASDAQ:AKRX): According to 10 Analysts, The short term target price has been estimated at $ 36.4.The target price could deviate by a maximum of $4.95 from the forecast price. In the near term, the target price could hit a high of $45 and a low of $ 30.

Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, William Blair, maintains their rating on the shares of Akorn (NASDAQ:AKRX). William Blair has a Outperform rating on the shares. As per the latest research report, the brokerage house lowers the price target to $36 per share from a prior target of $58. The rating by the firm was issued on March 23, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities,The director of Akorn Inc, Johnson Ronald M sold 7,542 shares at $31.49 on June 7, 2016. The Insider selling transaction had a total value worth of $237,498. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Akorn (NASDAQ:AKRX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.57 points or 1.88% at $29.68 with 1,161,218 shares getting traded. Post opening the session at $30.1, the shares hit an intraday low of $29.54 and an intraday high of $30.26 and the price was in this range throughout the day. The company has a market cap of $3,545 million and the number of outstanding shares have been calculated to be 119,427,471 shares. The 52-week high of Akorn (NASDAQ:AKRX) is $48.53 and the 52-week low is $17.57.

Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *